Growing the Integrase Inhibitor Class — Elvitegravir and Dolutegravir

Four years have passed since the licensing of the first HIV integrase inhibitor, raltegravir, and the drug has proven to be both effective and well tolerated. However, it requires twice-daily dosing, and suboptimal adherence can lead to drug resistance. In 2011, data emerged on two new integrase inhibitors that might address these limitations.

Elvitegravir is an investigational integrase inhibitor that requires pharmacologic boosting but can be administered once daily. At IAS this year, researchers reported the results of a phase III, manufacturer-sponsored, randomized trial comparing once-daily elvitegravir with twice-daily raltegravir in just over 700 treatment-experienced patients with virologic failure (JW AIDS Clin Care Aug …